Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print
Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.
A Randomized, Controlled Double-Blind Study Comparing The Efficacy And Safety Of Dose-Ranging Voclosporin With Placebo In Achieving Remission In Patients With Active Lupus Nephritis
Kidney Int 2019;95:219–31
Calcineurin inhibitors have the potential to increase the likelihood of complete renal remission (CRR) when added to standard-of-care induction therapy for LN.